Neville Rodie & Shaw’s Marker Therapeutics MRKR Stock Holding History

Neville Rodie & Shaw’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6,020	Closed	-$16K	–	248
2022 Q4	$16K	Hold	6,020	–	–	﹤0.01%	248
2022 Q3	$22K	Buy	6,020 +3,010	+100%	+$11K	﹤0.01%	245
2022 Q2	$10K	Hold	3,010	–	–	﹤0.01%	251
2022 Q1	$13K	Hold	3,010	–	–	﹤0.01%	262
2021 Q4	$29K	Hold	3,010	–	–	﹤0.01%	263
2021 Q3	$51K	Hold	3,010	–	–	﹤0.01%	256
2021 Q2	$84K	Hold	3,010	–	–	0.01%	258
2021 Q1	$67K	Hold	3,010	–	–	0.01%	255
2020 Q4	$44K	Hold	3,010	–	–	﹤0.01%	253
2020 Q3	$45K	Hold	3,010	–	–	﹤0.01%	243
2020 Q2	$62K	Hold	3,010	–	–	0.01%	241
2020 Q1	$57K	Hold	3,010	–	–	0.01%	223
2019 Q4	$87K	Hold	3,010	–	–	0.01%	244
2019 Q3	$154K	Hold	3,010	–	–	0.02%	235
2019 Q2	$238K	Hold	3,010	–	–	0.03%	220
2019 Q1	$199K	Hold	3,010	–	–	0.02%	243
2018 Q4	$167K	Hold	3,010	–	–	0.02%	227
2018 Q3	$272K	Hold	3,010	–	–	0.03%	220
2018 Q2	$284K	Sell	3,010 -9,200	-75%	-$469K	0.03%	213
2018 Q1	$413K	Hold	12,210	–	–	0.05%	179
2017 Q4	$479K	Buy	+12,210	New	+$375K	0.05%	171

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAM

AR Asset Management West Hollywood, California $517M AUM 18.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neville Rodie & Shaw's MRKR Position: Q1 2023 in Review

Neville Rodie & Shaw sold out of Marker Therapeutics (MRKR) in Q1 2023, closing a stake of 6,020 shares — an estimated $16K sold.

Neville Rodie & Shaw first reported a position in MRKR in Q4 2017 and held it in 21 quarters. The position peaked at $479K in Q4 2017. 30 funds tracked by Wall St. Rank hold MRKR as of Q1 2023.

Neville Rodie & Shaw reported no remaining Marker Therapeutics position as of Q1 2023 after selling out during the quarter.
Neville Rodie & Shaw sold 6,020 Marker Therapeutics shares in Q1 2023, an estimated $16K.
Neville Rodie & Shaw first reported a position in Marker Therapeutics in Q4 2017 and held it in 21 quarters.
Neville Rodie & Shaw's Marker Therapeutics position peaked at $479K in Q4 2017.
30 funds tracked by Wall St. Rank held Marker Therapeutics as of Q1 2023.

Based on Neville Rodie & Shaw's 13F filing for Q1 2023, filed 4 Apr 2023.